MOMENTUM IN OUR DYNAMIC PIPELINE BASED ON EMERGING DATA

WAVE 1[1] — WAVE 2[2]

CLINICAL-STAGE NMEs

TARGET APPROVAL	FY20	FY21	FY22	FY23	FY24	FY25/26		FY27 AND BEYOND		
ONCOLOGY		**mobocertinib** *2L NSCLC with EGFR exon 20 insertion mutation*[3]	**pevonedistat** *HR-MDS*	**mobocertinib** *1L NSCLC with EGFR exon 20 insertion mutation*	**pevonedistat** *Unfit AML* **TAK-007** *CD19+ hematologic malignancies*	**TAK-981** *Multiple cancers* **TAK-573** *R/R MM*	**TAK-605** *Multiple cancers*	**TAK-252** *Solid tumors* **TAK-169** *R/R MM*	**TAK-102** *Multiple cancers* **TAK-676** *Solid tumors*	**TAK-940** *CD19+ hematologic malignancies*
RARE GENETIC & HEMATOLOGY		**maribavir** *R/R CMV infect. in transplant* **TAK-609** *Hunter CNS (IT)*	**maribavir** *1L CMV infect. in HSCT*	**TAK-611** *MLD (IT)* **TAK-755** *cTTP*		**TAK-755** *iTTP, SCD*	**mezagitamab** *MG, ITP*	**TAK-607** *Complications of prematurity*		
NEUROSCIENCE				**soticlestat** *DEE*	**Orexin2R-ag** *(TAK-925/994) Narcolepsy T1*	**Orexin2R-ag** *Sleep Disorders* **WVE-120101** *Huntington's Disease*	**WVE-120102** *Huntington's Disease*	**TAK-341** *Parkinson's Disease* **TAK-041** *Anhedonia in MDD*	**TAK-071** *Parkinson's Disease* **TAK-653** *TRD*	**TAK-831** *CIAS NS*
GASTRO-ENTEROLOGY	**TAK-721**[4] *EoE*					**TAK-062** *Celiac Disease* **TAK-999** *AAT Liver Disease*	**TAK-101** *Celiac Disease* **TAK-951** *Nausea & vomiting*	**sibofimloc** *Crohn's Disease (post-op and ileitis)* **TAK-954** *POGD*	**TAK-671** *Acute Pancreatitis*	**TAK-039** *Hepatic encephalopathy*
VACCINES		**TAK-003** *Dengue Vaccine*				**TAK-426** *Zika Vaccine*		**TAK-214** *Norovirus Vaccine*		
PDT	**CoVIg-19**[5] *COVID-19 H-IG (Formerly TAK-888)*									

Orphan potential in at least one indication · Breakthrough and/or Fast Track Designations · China Breakthrough and/or Japan SAKIGAKE Designation · New addition to the pipeline

1. Projected approval dates depend on data read-outs; some Wave 1 target approval dates assume accelerated approval
2. Certain Wave 2 programs may be accelerated into Wave 1 depending on future data read outs
3. Approval date assumes filing on Phase 2 data
4. Approval expected Q4 FY20 or early Q1 FY21
5. The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) is sponsor of the study and manages execution of the trial. Timing of potential regulatory filing and approval is dependent on the study enrollment rate and successful completion of the clinical trial, and is subject to change.

Takeda's Fiscal Year ends March 31 of the following year; e.g."FY20" refers to the twelve month period ending March 31, 2021.
All timelines are approximate estimates of February 4, 2021.
For glossary of disease abbreviations please refer to appendix.

MAXIMIZING THE VALUE OF OUR APPROVED AND REGIONAL THERAPIES

	PHASE 1 & 2		PHASE 3				FILED		
ONCOLOGY	**NINLARO®** Proteasome inhibitor R/R MM triplet Tx (US, EU)	**ALUNBRIG®** ALK inhibitor 2L ALK+NSCLC 2nd gen TKI (GL) **NINLARO®** Proteasome inhibitor R/R MM doublet Tx (US, EU)	**ALUNBRIG®** ALK inhibitor 1L ALK+NSCLC (CN) **NINLARO®** Proteasome inhibitor Maint. ND MM no SCT (US, EU, CN)	**NINLARO®** Proteasome inhibitor Maint. ND MM post-SCT (US, EU) **ALUNBRIG®** ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL)	**ICLUSIG®** BCR-ABL inhibitor FL Ph+ ALL (US) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 2L mNSCLC combo w/atezolizumab (JP)	**Cabozantinib** *Exelixis* VEGFR/RTK inhibitor mCRPC combo w/atezolizumab (JP)	**NINLARO®** Proteasome inhibitor Maint. ND MM no SCT (JP) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 2L HCC (JP)	**ALUNBRIG®** ALK inhibitor 1L & 2L ALK+NSCLC (JP) **ICLUSIG®** BCR-ABL inhibitor TKI res. chronic phase CML (US)	**ADCETRIS®** *Seattle Genetics* CD30 ADC CTCL (CN) **Cabozantinib** *Exelixis* VEGFR/RTK inhibitor 1L RCC combo w/nivolumab (JP)
RARE GENETIC & HEMATOLOGY		**NATPARA®** PTH replacement Hypothyrodism (JP)	**TAKHZYRO®** Anti-kallikrein mAb HAE pediatric (GL) **TAKHZYRO®** Anti-kallikrein mAb HAE (JP)	**OBIZUR®** *Ipsen* FVIII replacement CHAWI (US, EU) **TAKHZYRO®** Anti-kallikrein mAb BMA (GL)	**VONVENDI®** vWF replacement vWD Adult Prophylaxis (GL) **VONVENDI®** vWF replacement vWD Pediatric on-demand (GL)	**ADYNOVATE®** Pediatric HemA (EU)	**TAKHZYRO®** Anti-kallikrein mAb HAE prophylaxis (CN)		
NEUROSCIENCE									
GASTRO-ENTEROLOGY		**ENTYVIO®** α4β7 mAb Pediatric UC/CD (GL)	**ENTYVIO®** α4β7 mAb GvHD Prophylaxis (EU, JP)	**ALOFISEL®** mesenchymal stem cells Perianal Fistulas in CD (US, JP) **ENTYVIO®** α4β7 mAb SubQ CD (US, JP)	**Vonoprazan** PCAB Oral disintegrated tablet formulation (JP) **Vonoprazan** PCAB H. Pylori (CN)		**ENTYVIO®** α4β7 mAb SubQ UC (US, JP)	**Vonoprazan** PCAB Reflex Esophagitis Maintenance (CN) **Vonoprazan** PCAB Duodenal ulcer (CN)	**GATTEX®** GLP-2R agonist Pediatric-SBS (JP) **GATTEX®** GLP-2R agonist Adult-SBS (JP)
VACCINES	**TAK-919** *Moderna* COVID-19 Vaccine (JP)	**TAK-019**[1] *Novavax* COVID-19 Vaccine (JP)							
PDT			**CUVITRU®** IgG 20% (human) subcutaneous PID (JP)	**HYQVIA®** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase CIDP (US, EU)	**HYQVIA®** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)				

● Orphan Drug Designation (in any region / indication for a given asset) ● Pivotal Ph-2 study ▶ Clinical stage up since Q2 FY20 ✓ Approved since Q2 FY20
New regional addition to the pipeline ✗ Discontinued/deprioritized

Pipeline as of February 4, 2021; region abbreviations: GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas 1. Pending first subject in